Anticonvulsant effects of a novel aminobenzamide (LY201116) in mice
| Autor: | R.R. Lawson, J.D. Leander, David W. Robertson |
|---|---|
| Rok vydání: | 1988 |
| Předmět: |
Male
Phenytoin medicine.medical_treatment Administration Oral Mice Inbred Strains Pharmacology Mice Cellular and Molecular Neuroscience chemistry.chemical_compound Oral administration Convulsion medicine Animals Benzamide ED50 Electroshock business.industry Carbamazepine Anticonvulsant chemistry Mechanism of action Phenobarbital Benzamides Injections Intravenous Anticonvulsants medicine.symptom business medicine.drug |
| Zdroj: | Neuropharmacology. 27:623-628 |
| ISSN: | 0028-3908 |
| DOI: | 10.1016/0028-3908(88)90184-0 |
| Popis: | The drug 4-amino-N-(2,6-dimethylphenyl)benzamide(LY201116) is a potent and selective anticonvulsant in the maximal electric shock test in mice. The ED50 values after oral and intravenous administration were 1.7mg/kg and 0.51 mg/kg, respectively. For comparison, the oral and intravenous ED50 values for the anticonvulsant phenytoin which is selective for the maximal electric shock test were 9.1 and 8.5 mg/kg, respectively. After oral administration, LY201116 had a protective index (ED50 to produce neurological impairment, divided by ED50 on the maximal electric shock) of 13.5. After 4 days of administration, there was no evidence of the development of tolerance to the anticonvulsant effects of LY201116. The hexobarbital-induced sleeping time was not significantly affected by either acute or chronic administration of LY201116 for 4 days. In combination studies with the anticonvulsants phenytoin and carbamazepine which are selective for the maximal electric shock test, LY201116 produced dose-additive effects which suggest that it produces its anticonvulsant action through the same mechanism of action as these prototype anticonvulsants. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|